Volanesorsen
PreclinicalRNA therapy
Volanesorsen is a rna therapy that works as Apoc-III Antisense.[2] It is being investigated across 1 indication, with its most advanced program in Preclinical.[1]
Volanesorsen is one of 21 aso programs targeting Hypercholesterolemia. It is currently in Preclinical.
1
Indications
6
Total Trials
0
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
24 competitors in Hypercholesterolemia
#DrugCompanyPhaseTrials
1Crestor
AstraZenecaApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Zocor
OOrganon and Co
Approved
Leqvio
NovartisApproved
Livalo
MMedicure
Approved
Praluent
RegeneronPhase 3
Niacor
AbbVieApproved
Lesinurad
EEsperion Therapeutics, Inc.
Approved
Altoprev
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Questran
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Familial Chylomicronemia Syndrome3 trials
Familial Partial Lipodystrophy1 trial
Cardiac Repolarization1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Volanesorsen. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Apoc-III Antisense[2]
- Modality
- RNA therapy[2]
- Highest Phase
- Preclinical[1]
- Company
- AAkcea Therapeutics